IL230391B - Combination als therapy - Google Patents

Combination als therapy

Info

Publication number
IL230391B
IL230391B IL230391A IL23039114A IL230391B IL 230391 B IL230391 B IL 230391B IL 230391 A IL230391 A IL 230391A IL 23039114 A IL23039114 A IL 23039114A IL 230391 B IL230391 B IL 230391B
Authority
IL
Israel
Prior art keywords
als
combined treatment
treatment
combined
Prior art date
Application number
IL230391A
Other languages
English (en)
Hebrew (he)
Inventor
Cedarbaum Jesse
Mao John
Malik Fady
A Wolff Andrew
Original Assignee
Cytokinetics Inc
Cedarbaum Jesse
Mao John
Malik Fady
A Wolff Andrew
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc, Cedarbaum Jesse, Mao John, Malik Fady, A Wolff Andrew filed Critical Cytokinetics Inc
Publication of IL230391B publication Critical patent/IL230391B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL230391A 2011-07-13 2014-01-09 Combination als therapy IL230391B (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161507381P 2011-07-13 2011-07-13
US201161544533P 2011-10-07 2011-10-07
US201261637759P 2012-04-24 2012-04-24
US201261637770P 2012-04-24 2012-04-24
US201261646699P 2012-05-14 2012-05-14
PCT/US2012/046523 WO2013010015A2 (en) 2011-07-13 2012-07-12 Combination als therapy

Publications (1)

Publication Number Publication Date
IL230391B true IL230391B (en) 2019-03-31

Family

ID=47506929

Family Applications (1)

Application Number Title Priority Date Filing Date
IL230391A IL230391B (en) 2011-07-13 2014-01-09 Combination als therapy

Country Status (16)

Country Link
US (1) US10272082B2 (forum.php)
EP (1) EP2731611B1 (forum.php)
JP (2) JP6145946B2 (forum.php)
KR (1) KR101951220B1 (forum.php)
CN (2) CN104039148A (forum.php)
AU (2) AU2012281042B2 (forum.php)
BR (1) BR112014000742A2 (forum.php)
CA (1) CA2849213A1 (forum.php)
EA (2) EA028060B1 (forum.php)
HK (1) HK1197178A1 (forum.php)
IL (1) IL230391B (forum.php)
IN (1) IN2014DN00200A (forum.php)
PH (1) PH12014500094A1 (forum.php)
SG (1) SG10201605707UA (forum.php)
WO (1) WO2013010015A2 (forum.php)
ZA (1) ZA201400236B (forum.php)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US20160263110A1 (en) * 2013-11-04 2016-09-15 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis
PT3137622T (pt) * 2014-04-29 2022-03-08 Cytokinetics Inc Métodos para reduzir o declínio da capacidade vital
PT3220891T (pt) * 2014-11-21 2019-10-31 Biohaven Pharm Holding Co Ltd Formulação sublingual de riluzol
EP3220890A1 (en) * 2014-11-21 2017-09-27 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
US10092564B2 (en) 2016-03-25 2018-10-09 Ab Science Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
EP4031135A4 (en) * 2019-09-20 2023-10-18 Icahn School of Medicine at Mount Sinai CONTROLLED RELEASE FORMULATIONS OF RILUZOLE AND USES THEREOF

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
IT1156732B (it) 1978-05-10 1987-02-04 Roussel Maestretti Spa Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione
US4668686A (en) 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4943573A (en) 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0641135A (ja) 1992-07-21 1994-02-15 Nippon Soda Co Ltd イミダゾプテリジン誘導体及びその製造方法
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2333770A1 (en) 1998-06-04 1999-12-09 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
SK286788B6 (sk) 1999-10-08 2009-05-07 Grnenthal Gmbh Bicyklické deriváty imidazo-3-yl-amínu, spôsob ich výroby, ich použitie a liečivá obsahujúce tieto látky
MXPA02002837A (es) 1999-10-08 2002-08-30 Gr Nenthal Gmbh Derivados biciclicos de imidazo-5-il-amina.
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
US20030083318A1 (en) * 2001-10-25 2003-05-01 Jean-Pierre Julien Therapy for neurodegenerative diseases
US20040235801A1 (en) * 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
AU2003294249A1 (en) 2002-11-08 2004-06-03 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
ATE461196T1 (de) 2003-06-26 2010-04-15 Merck Sharp & Dohme Benzodiazepin-cgrp-rezeptor-antagonisten
WO2005002520A2 (en) 2003-07-01 2005-01-13 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2007515429A (ja) 2003-12-19 2007-06-14 エリクシアー ファーマシューティカルズ， インコーポレイテッド 障害を治療する方法
EP1715855A4 (en) 2004-01-29 2010-06-16 Elixir Pharmaceuticals Inc ANTIVIRAL DRUGS
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2005289644A1 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
MX2007010068A (es) 2005-02-16 2007-10-10 Schering Corp Piperazino-piperidinas con actividad antagonista de cxcr3.
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
US20090082370A1 (en) 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
EP3719018B1 (en) 2006-04-25 2025-08-27 Astex Therapeutics Ltd Purine and deazapurine derivatives as pharmaceutical compounds
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US20100173930A1 (en) 2006-08-01 2010-07-08 Alex Muci Certain Chemical Entities, Compositions and Methods
CN101522681B (zh) * 2006-08-02 2012-10-03 赛特凯恩蒂克公司 特定的化学个体、组合物和方法
PL2583970T3 (pl) 2006-08-02 2016-05-31 Cytokinetics Inc Określone cząstki chemiczne, kompozycje i sposoby zawierające imidazopirymidyny
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
ATE543819T1 (de) 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
JP5491199B2 (ja) 2007-01-19 2014-05-14 アルデア バイオサイエンシズ，インコーポレイティド Ｍｅｋのインヒビター
WO2008121333A1 (en) 2007-03-30 2008-10-09 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
EP2018854A1 (en) * 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
CA2713864A1 (en) 2008-02-04 2009-08-13 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
CA2730473A1 (en) 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
ES2554375T3 (es) 2008-11-25 2015-12-18 University Of Rochester Inhibidores de las MLK y métodos de uso
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
CA2765876A1 (en) * 2009-06-19 2010-12-23 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
SG10201701101YA (en) 2012-04-02 2017-04-27 Cytokinetics Inc Methods for improving diaphragm function
EP2836590A4 (en) 2012-04-11 2016-04-13 Cytokinetics Inc METHOD FOR IMPROVING THE RESISTANCE TO SKELETON MUSCULAR FEEDING
PT3137622T (pt) 2014-04-29 2022-03-08 Cytokinetics Inc Métodos para reduzir o declínio da capacidade vital

Also Published As

Publication number Publication date
EA201490011A1 (ru) 2014-08-29
BR112014000742A2 (pt) 2016-08-23
CA2849213A1 (en) 2013-01-17
PH12014500094A1 (en) 2014-03-17
EP2731611A2 (en) 2014-05-21
EP2731611A4 (en) 2015-02-18
AU2012281042A1 (en) 2014-01-30
CN109316480A (zh) 2019-02-12
NZ619924A (en) 2016-02-26
EA201791043A1 (ru) 2017-09-29
ZA201400236B (en) 2014-10-29
HK1197178A1 (en) 2015-01-09
EP2731611B1 (en) 2019-09-18
CN104039148A (zh) 2014-09-10
US10272082B2 (en) 2019-04-30
KR20140074270A (ko) 2014-06-17
KR101951220B1 (ko) 2019-02-22
WO2013010015A3 (en) 2014-05-15
EA028060B1 (ru) 2017-10-31
JP6145946B2 (ja) 2017-06-14
WO2013010015A2 (en) 2013-01-17
US20140243344A1 (en) 2014-08-28
AU2012281042B2 (en) 2016-07-14
JP2014520856A (ja) 2014-08-25
AU2016244263A1 (en) 2016-11-03
SG10201605707UA (en) 2016-09-29
JP2017128610A (ja) 2017-07-27
IN2014DN00200A (forum.php) 2015-06-05

Similar Documents

Publication Publication Date Title
BR112014007603A2 (pt) métodos de tratamento do câncer
DK2761553T3 (da) Betalingssystem
EP2698463A4 (en) WASHING METHOD
LT2707030T (lt) Vėžio gydymas
EP2663304A4 (en) COMBINATION THERAPY
HUE046667T2 (hu) Rák kombinatív kezelése
BRDI7105193S (pt) Configuração aplicada em bolsa
DK3421470T3 (da) Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
IL249039A0 (en) 2-thiopyrimidinones
BR112013033974A2 (pt) terapia de combinação
DK2760886T3 (da) Immunocytokin-kombinationsterapi
EP2725663A4 (en) CONNECTOR
FI20115876A0 (fi) Yhdistelmähoito
IL230391B (en) Combination als therapy
DK2489413T5 (da) Behandlingsapparat
CO6880064A2 (es) Métodos terapéuticos
EP2763255A4 (en) Connector
FI20116093L (fi) Vettä käsittelevä laitos
FI20115640A0 (fi) Yhdistelmähoito
IL237150A0 (en) Treatment regimens
IL228729A0 (en) Treatment regimens
CO6950447A2 (es) Aparato de tratamiento de espalda
DK2607881T3 (da) Koncentrationsapparat
FI20115020A0 (fi) Käsittely-yksikkö
FI20115905A0 (fi) Käsittelyjärjestely

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed